Neoadjuvant anti-programmed death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial - Eichhorn, Florian; Klotz, Laura Valentina; Bischoff, Helge; Thomas, Michael; Lasitschka, Felix; Winter, Hauke; Hoffmann, Hans; Eichhorn, Martin E. (BMC cancer, 2019)
Gesehen am 10.03.2020